This edition of the Generics Bulletin podcast sees editor Dave Wallace, deputy editor Dean Rudge and reporters Urtė Fultinavičiūtė and Adam Zamecnik discuss key topics of 2024, including the latest rankings of the Generics Bulletin Top 50, Amgen’s surprise launch of a US Eylea biosimilar, the EU’s Urban Waste Water Treatment Directive and supply-chain issues for the off-patent sector.
This year’s Generics Bulletin Top 50 was published across a series of four articles, starting here.
We covered the recent passage of the EU’s Urban Waste Water Treatment Directive in multiple articles.
We have written regularly about Amgen’s launch of a biosimilar rival to Eylea in the US since our initial coverage.
And our coverage of supply-chain issues includes the formation of the Critical Medicines Alliance and progress towards a Critical Medicines Act, as well as the recent British Generic Manufacturers Association report on UK supply-chain obstacles and subsequent Royal Pharmaceutical Society recommendations.
